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Abstract
Background: Loss of functional Myostatin results in a dramatic increase in skeletal muscle mass. It is unknown
what role miRNAs play in Myostatin mediated repression of skeletal muscle mass. We hypothesized that Myostatin
genotype would be associated with the differential expression of miRNAs in skeletal muscle.
Findings: Loss of functional Myostatin resulted in a significant increase (p < .001) in miR-1, miR-133a, miR-133b,
and miR-206 expression. In contrast, Myostatin genotype had no effect (P > .2) on miR-24 expression level.
Myostatin genotype did not affect the expression level of MyoD or Myogenin (P > 0.5).
Conclusions: Myostatin may regulates the expression of miRNAs such as miR-133a, miR-133b, miR-1, and miR-206 in
skeletal muscle as it has been observed that the expression of those miRNAs are significantly higher in myostatin
null mice compared to wild type and heterozygous mice. In contrast, expression of myogenic factors such as
MyoD or Myogenin has not been affected by myostatin in the muscle tissue.
Background
miRNAs have generated strong interest among research-
ers in different fields to understand their biosynthesis,
mechanism of action, and identification of their targets.
First discovered in the caenorhabditis elegans as small
temporal RNAs required for proper developmental tim-
ing, miRNA are a family of highly conserved, non-
coding, 22 nucleotide [1] double-stranded RNA products
that post-transcriptionally regulate gene action [1-4].
Sampere et al. (2004) first identified the expression of
the muscle specific miRNas such as miR-1, -133a and
-206 [5]. Their expression was highly enriched in both
human and mouse heart and skeletal muscle. Subse-
quently, several miRNA expression profiling studies
have consistently shown miR-1, -133a and -206 to be
muscle specific [6-11]. These muscle specific expressions
are evolutionarily conserved among animals [12]. Over
expression of miR-1 and miR-133 during the in-vitro
development of embryoid bodies from mouse embryonic
stem cells demonstrated that distinct steps in muscle
development are specified by cooperative and opposing
interactions between miR-1 and miR-133.
Given that miRNAs have been shown to play roles in
the regulation of satellite cell proliferation and
differentiation, the current study was carried out to eval-
uate the effect of loss of Myostatin function on skeletal
muscle miRNA expression.
Methods
Animal Experimentation
The present experiment was conducted with mice that
were MSTN
-/- [13], MSTN
+/+ and MSTN
+/- (either
sex). MSTN
+/- mice were mated to produce MSTN
-/-
(n = 9), MSTN
+/+ (n = 10) and MSTN
+/- (n = 10) ani-
mals. The mice were housed in a temperature- and
humidity-controlled room and maintained at 22°C on a
12-h light-dark cycle with food and water provided ad
libitum. At 1 week of age, mice were individually identi-
fied and genotyped. Mice were weaned at 21 days of
age. At 35 days of age mice were euthanized by CO2
asphyxiation. The pectoralis muscles were excised, flash-
frozen in liquid nitrogen, and stored at -80°C until RNA
isolation. The Iowa State University Institutional Animal
Care and Use Committee approved all procedures that
involved mice.
DNA Isolation and Genotyping
T h eD N Aw a si s o l a t e db ys t a n d a r dp r o t o c o lw i t hf e w
modifications [14] from toes clipped at seven days after
birth. Myostatin genotyping was completed with a * Correspondence: jreecy@iastate.edu
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Mstn1-5’-GGC ATC TGT TCT GCT ATT ACG TGC-
3’,Mstn2-5’-GTG CGA TAA TCC AGT CCC AT-3’ and
Mstn3-5’-GTG GAT GTG GAA TGT GTG CGA GG-
3’. The PCR amplification reaction contained 50 ng
DNA, 0.2 μl (50 pmol) of each primer, 5 μl of 2X Green
GoTaq® Reaction Buffer (pH 8.5) (GoTaq® DNA Poly-
merase, 400 μM dATP, 400 μM dGTP, 400 μMd C T P ,
400 μM dTTP and 3 mM MgCl2). The PCR amplifica-
tion was carried out in a programmable thermal cycler
(MJ research) using the following program: 3 minutes at
92°C, 15 seconds at 92°C, 30 seconds at 65°C, 30 sec-
onds at 72°C followed by 39 cycles of 15 seconds at
92°C, 30 seconds at 65°C, 30 seconds at 72°C, final
extension of 10 minutes at 72°C. The PCR products
were size separated on 1.5% agarose gels to confirm
genotype based on the amplification of target regions.
RNA Isolation
Total RNA was isolated from left pectoralis muscle
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
according to manufacturer’s directions. The RNA was
purified by columns (Qiagen sciences, Maryland, USA)
and treated with DNase I (Qiagen, Maryland, USA) to
remove genomic DNA contamination. The RNA con-
centration was measured by UV absorbance. RNA sam-
ples with an A260/280 ratio of = > 2.0 were used for RT-
PCR.
cDNA Synthesis and Real Time PCR for MYOD and
Myogenin
Reverse transcription of RNA was performed (Invitro-
gen, Carlsbad, CA) by adding 10 μl of (500 ng) total
RNA, 1 μl of Oligo (dT) 12-18 (500 μg/ml), and 1 μl1 0
mM dNTP incubated at 65°C for 5 minutes and imme-
diately chilled on ice. Then, each component was added
in the indicated order 4 μl of (5×) first strand RT buffer,
0.1 M DTT 1 μl, RNaseOUT. RNase Inhibitor 1 μl,
incubated at 42°C for 2 min. 1 μl( 5 0u n i t s )o fS u p e r -
Script II RT was then added to each tube mix, and incu-
bated at 42°C for 50 min. The reactions were terminated
at 70°C for 15 min. Chill on ice.
Real-time PCR was performed on Stratagene 4000×
Real-Time PCR System. Quantitative PCR reactions
were optimized for annealing temperature and primer
concentration. Real-time PCR reactions were performed
in triplicate and template controls (NTCs) were run for
each assay under the same conditions. End-point PCR
was then performed in 10 μl reaction containing 5 μl
SBYR green Master Mix, 3.2 μl of autoclaved nuclease
free water, 1 μl diluted RT product (Minimum1:10 but
MyOD undiluted cDNA was used) and 0.4 μlf o r w a r d
and reverse primers (specific to genes i.e MyoD
F-5’-TACAGTGGCGACTCAGATGC-3’ and R-5’-
GCTCC ACTATGCTGGACAGG-3’ and MyoG
F-5’-CTACAGGCCTTGCTCAGCTC-3’ and R-5’-
ACGATGGACGTAAGGGAGTG-3’) for 40 cycles (two
steps: 95°C for 10 minutes followed by 40 cycles 95°C
15s followed by 58°C for 60 s). Standard curves were
generated with known amounts (molecules) of cDNA
and run with each PCR run. Gene expression levels
were normalized to the level of b-actin expression,
which we have shown to be unresponsive to Myostatin
expression level [15], and are reported relative to Myos-
tatin wild-type expression level.
Detection of Mature miRNAs by TaqMan assays
Five mouse Taqman miRNA assays were purchased
from Applied Biosystems. Reverse transcription reac-
tions (15 μl) containing, 1.5 μl of 10× reverse transcrip-
tion buffer, 1.0 μlo fM u l t i S c r i b e ™reverse transcriptase
(50 U/μl), 0.15 μl of 100 mM dNTPs (with dTTP) and
0.19 μlo fR N a s ei n h i b i t o r( 2 0U / μl ) ,4 . 1 6o fN u c l e a s e -
free water were mixed by brief centrifugation, 5 μlo f
total RNA (50 ng) was added and mixed well, 3 μlo f1 ×
looped-primers were added (specific for microRNA) and
mixed well and incubated for 30 min each, at 16°C,
42°C and 5 minutes at 85°C according to manufacturer’s
directions. The cDNA was diluted to a minimum of
1:15 with nuclease free water and 1.33 μlw a su s e di n
real time PCR.
Real-time PCR was performed on Stratagene 4000×
Real-Time PCR System. During the target amplification
step, the AmpliTaq® Gold DNA polymerase amplifies
target cDNA synthesized from the RNA sample, using
sequence-specific primers from the TaqMan Assay.
Real-time PCR reactions based on TaqMan® reagent
chemistry were performed in triplicate and template
controls were run for each assay under the same condi-
tions. End-point PCR was then performed in 20 μl reac-
tions that contained 10.00 μl TaqMan 2× Universal PCR
Master Mix No AmpErase UNG, 7.67 μlo fa u t o c l a v e d
nuclease free water, 1.33 μl diluted RT product (Mini-
mum1:15) and 1 μl miRNA-specific PCR probe for 40
cycles (two steps: 95°C for 10 minutes followed by 40
cycles 95°C 15s followed by 60°C for 60 s). miRNA
expression levels were normalized to the level of miR-24
expression, which was unresponsive to Myostatin
expression level, to correct for differential cDNA
content.
Statistical analysis
Student’s t-test was used to determine whether a signifi-
cant difference existed among MSTN
-/-,M S T N
+/- and
MSTN
+/+ animals. The P <0 . 0 5w a sd e n o t e db ya n
asterisk.
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Pectoralis muscles from 29 mice were examined for dif-
ferential expression of five microRNAs and two genes.
The weight of MSTN
-/- pectoralis muscle (108 ± 5.9
mg) was significantly greater (p < 0.001) than MSTN
+/+
pectoralis muscle (72.6 ± 5.9 mg) 35 days after birth.
Expression of muscle-specific miRNAs and myogenic
factors
The expression level of miR-133a (p < 0.0001), miR-
133b (p < 0.001), miR-1 (p < 0.001), and miR-206 (p <
.0001) was greater in Myostatin-null animals as com-
pared to wild type and heterozygous animal (Figure 1).
In all cases, the expression level of miRNAs was equiva-
lent in MSTN
+/- and MSTN
+/+ muscle. In contrast,
miR-24 expression level was not affected by Myostatin
genotype (data not shown). Myostatin genotype had no
significant effect on the expression level of MyoD or
Myogenin (Figure 2).
Discussion
Accumulating evidence supports a role for miRNAs
in the regulation of myogenesis [16]. miR-1/-206 and
miR-133 play opposing roles in modulating skeletal
muscle proliferation and differentiation. The miR-1 and
miR-206 promote myogenesis, while miR-133 inhibits
myoblast differentiation and promotes proliferation by
repressing serum response factor and a key splicing
factor [17-20].
In this study, we observed higher miR-1, miR-133a,
miR-133b, and miR-206 expression levels in the pectora-
lis muscle of MSTN
-/- mice as compared to MSTN
+/+
and MSTN
+/- animals. This increased level of miR-1,
-133a, -133b, and -206 expressions was consistent with
the enhanced skeletal muscle growth observed in
MSTN
-/- mice. In order to sustain the increased growth
observed in Myostatin-null mice elevated satellite cell
proliferation, which is regulated by miR-133 [19] and
differentiation, which is regulated by miR-1 and -206
[19,19,21], must occur. However, this would also indi-
cate that the increased levels of miRNA would need to
occur in a cell-type specific manner.
Recently, Davis et al. (2008) reported that SMAD pro-
teins control Drosha-mediated miRNA maturation. They
observed that TGF-b and BMP4 treatment promoted
the formation of specific miRNA/SMAD complexes,
Figure 1 Relative expression of mature microRNAs in the mouse pectoralis muscle. Real-time PCR expression values were normalized to
miR-24 and then reported relative to MSTN
+/+ levels. Data are means ± S.E. *** p, <0.0001. MSTN +/+ is a wild-type mouse, MSTN -/+ represents
a heterozygous Myostatin-null mouse, and MSTN -/- represents a homozygous Myostatin-null mouse.
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observed increased mature miRNA levels in the absence
of functional Myostatin, which is a TGF-b super family
member. This observation indicates the possibility that
TGF-b super family member can both promote and
inhibit maturation of specific miRNAs [22].
Alternatively, the increased miRNA expression
observed in the absence of functional Myostatin could
be the result of enhanced Myf5 and MEF2A gene
expression. Previously, we reported that loss of func-
tional Myostatin increased both Myf5 and MEF2A gene
expression [15]. Recently, Sweetman et al. (2008)
reported that over expression of Myf5 was capable of
inducing miR-1 and miR-206 [ 2 3 ] .W h i l e ,m i R - 1a n d
miR-206 expression was lost in Myf5
-/- mice, which
indicates that miR-1 and miR-206 lie downstream of
Myf5. Similarly, Liu et al. (2007) identified an intragenic
MEF2-dependent enhancer that directed miR-1 and
miR-133a expression levels. Thus, it is possible that the
observed increase in muscle-specific miRNAs is the
result of increased Myf5 and MEF2A expression, which
are the result of loss of functional Myostatin [24].
Interestingly, none of the miRNAs exhibited an addi-
tive expression level with the increasing loss of Myosta-
tin (ie. miRNA expression in heterozygotes should be
intermediate between Myostatin-null and wild-type).
Myostatin appears to control miR-1, -133a, -133b,a n d
-206 in a dominant manner, as the presence of func-
tional Myostatin (wild-type and heterozygous mouse
muscle) similarly regulated miRNA expression. Given
that skeletal muscle mass was increased in heterozygous
Myostatin mice, this would seem to indicate that miR-1,
-133a, -133b, and -206 are not required for the observed
increased muscle mass observed in Myostatin-null and
heterozygous mice. Alternatively, it is also possible that
miR-1, -133a, -133b,a n d-206 are very sensitive to
Myostatin and even low levels of Myostatin, such as
those observed in MSTN
+/- mice, can inhibit their
expression. Thus, it is possible that miR-1, -133a, -133b,
and -206 are necessary for the increased muscle mass
observed in Myostatin-null mice, but they are not rate
limiting.
Conclusions
The expression of miR-133a (p < .0001), miR-133b (p <
.001), miR-1 (p < .001), and miR-206 (p < .0001) were
significantly higher in myostatin null mice compared to
wild type animals. Therefore, myostatin may regulate
the expression of miRNAs in skeletal muscle. Similarly,
myostatin has no effect on expression of myogenic fac-
tors such as MyoD or Myogenin in the muscle tissue.
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Figure 2 Relative expression of myogenic factors in the mouse pectoralis muscle. Real-time PCR expression values were normalized to b-
actin and are reported relative to MSTN
+/+ levels. The graph represents the mean (± SE) fold change in gene expression.
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